<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869986</url>
  </required_header>
  <id_info>
    <org_study_id>12791</org_study_id>
    <secondary_id>I3E-BM-MSAE</secondary_id>
    <secondary_id>2006-001947-70</secondary_id>
    <secondary_id>MBP8298-RR01</secondary_id>
    <nct_id>NCT00869986</nct_id>
  </id_info>
  <brief_title>A Study for Patients With Relapsing Remitting Multiple Sclerosis</brief_title>
  <acronym>MINDSET01</acronym>
  <official_title>A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMS Technology Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if dirucotide is safe and effective in treating patients&#xD;
      with relapsing remitting multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to confirmed worsening of disability by Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>baseline, 15, 24 and 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to confirmed worsening of disability by Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>baseline, 15, 24 and 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients relapse-free</measure>
    <time_frame>15, 24, and 27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity analysis of T2 and Gadolinium enhancing lesions</measure>
    <time_frame>15 and 27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dirucotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dirucotide</intervention_name>
    <description>500mg, intravenous, every 6 months for 15 months</description>
    <arm_group_label>Dirucotide</arm_group_label>
    <other_name>MBP8298</other_name>
    <other_name>LY2820671</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>intravenous, once every six months for 15 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, 18-50 years of age&#xD;
&#xD;
          2. Relapsing-remitting multiple sclerosis (RRMS) according to &quot;Diagnostic criteria for&#xD;
             multiple sclerosis: 2005 revisions to the McDonald Criteria&quot; (Annals of Neurology 58:&#xD;
             840-846)&#xD;
&#xD;
          3. At least 2 years history of MS before trial entry&#xD;
&#xD;
          4. Documented history of 2 or more exacerbations in the 2 years prior to trial entry&#xD;
&#xD;
          5. Stable neurological status for at least 30 days before first study drug administration&#xD;
&#xD;
          6. Have an EDSS from 0-5.5&#xD;
&#xD;
          7. If female, she must either&#xD;
&#xD;
               -  be post-menopausal or surgically sterilized; or&#xD;
&#xD;
               -  use a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or&#xD;
                  condom with spermicide, for the duration of the study; and&#xD;
&#xD;
               -  be neither pregnant nor breast-feeding&#xD;
&#xD;
          8. Willingness and ability to comply with the protocol for the duration of the study&#xD;
&#xD;
          9. In the Investigator's opinion, subjects must be reliable, compliant, and agree to&#xD;
             cooperate with all trial evaluations&#xD;
&#xD;
         10. Subject must be able and willing to give meaningful, written informed consent prior to&#xD;
             participation in the trial, in accordance with regulatory requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have Clinically Isolated Syndrome (CIS), Secondary Progressive MS (SPMS), Primary&#xD;
             Progressive MS (PPMS)&#xD;
&#xD;
          2. Any known malignancy, or history of malignancy, with the exclusion of basal cell&#xD;
             carcinoma&#xD;
&#xD;
          3. Have active, clinically significant liver, renal or bone marrow disease accompanied&#xD;
             with significant laboratory abnormalities in the range of grade I or more as defined&#xD;
             by Common Toxicity Criteria (CTC),&#xD;
&#xD;
          4. Clinically significant ECG abnormalities at screening&#xD;
&#xD;
          5. Have the presence of systemic disease that, in the opinion of the investigator, might&#xD;
             interfere with subject safety, compliance or evaluation of the condition under study&#xD;
             (e.g. insulin dependent diabetes, lyme disease, clinically significant cardiac,&#xD;
             hepatic, or renal disease, Human Immunodeficiency Virus, or Human T-Cell Lymphotrophic&#xD;
             Virus Type-1)&#xD;
&#xD;
          6. Have current autoimmune disease, compromised immune function or infection&#xD;
&#xD;
          7. History of allergic reactions to glatiramer acetate&#xD;
&#xD;
          8. Steroid therapy within 30 days prior to first study specific procedure, or any other&#xD;
             treatment known to be used for putative or experimental MS treatment&#xD;
&#xD;
          9. Therapy with ÃŸ-interferon, glatiramer acetate, statins, copaxone or nonspecific&#xD;
             phosphodiesterase inhibitors within 3 months prior to first study-specific test&#xD;
&#xD;
         10. Therapy with mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other&#xD;
             immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or&#xD;
             non-recombinant cytokines or plasma exchange within 6 months prior to performance of&#xD;
             the first study-specific test, with the exception of corticosteroids or ACTH for&#xD;
             relapse treatment&#xD;
&#xD;
         11. Treatment at any time with an altered peptide ligand, cladribine, total lymphoid&#xD;
             irradiation, monoclonal anti-body treatment e.g. anti-CD4, anti-CD52, anti-VLA4,&#xD;
             Anti-CD20,&#xD;
&#xD;
         12. Any contraindications for MRI, e.g. pacemaker or known allergy to Gadolinium- DTPA&#xD;
&#xD;
         13. Participation in any other trial of an investigational agent within 90 days prior to&#xD;
             screening&#xD;
&#xD;
         14. History of alcohol or drug abuse as specified by the Diagnostic and Statistical Manual&#xD;
             of Mental Disorders, 4th edition (DSM-IV) within the year before screening&#xD;
&#xD;
         15. Any medical, psychiatric or other condition that could result in a subject not being&#xD;
             able to give fully informed consent, or to comply with the protocol requirements&#xD;
&#xD;
         16. Any other condition that, in the Investigator's opinion, makes the subject unsuitable&#xD;
             for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am - 5pm Eastern Time (UTC/GMT)-5 hours,EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Medical School</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical City Hospital No. 11</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP J A Reimana</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnitsa State Medical University</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <disposition_first_submitted>September 7, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>September 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 9, 2010</disposition_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

